Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
Executive Summary
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
You may also be interested in...
Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.
Amgen Hopes Kyprolis Label Expansion Will Give It A Leg Up In The Myeloma Market
Firm believes addition of data from the ENDEAVOR trial, and new claims, will establish the proteasome inhibitor as a backbone of choice across lines of therapy.
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
The multiple myeloma treatment landscape is poised for a shakeup following the FDA approval of three new drugs to treat the incurable cancer, but with all the competition, determining which drugs to use when and in which patients won’t necessarily be straightforward.